(vianews) - shares of erytech pharma (cac 40: eryp.pa) jumped by a staggering 10.77% to 0.91 € at 10:55 est on monday, following the last session's upward trend. cac 40 is rising 0.4% to 7,158.26 €, following the last session's downward trend. this seems, as yet, a somewhat positive trend trading session today.
about erytech pharma
erytech pharma s.a., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in france and the united states. its lead product candidate is eryaspase, which is in phase 3 clinical development for the treatment of second-line pancreatic cancer, and in phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. the company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. the company was incorporated in 2004 and is headquartered in lyon, france.
earnings per share
as for profitability, erytech pharma has a trailing twelve months eps of -3.99 €.
volume
today's last reported volume for erytech pharma is 286584 which is 50.97% below its average volume of 584624.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, erytech pharma's stock is considered to be oversold (<=20).
volatility
erytech pharma's last week, last month's, and last quarter's current intraday variation average was a negative 3.09%, a positive 4.25%, and a positive 5.38%.
erytech pharma's highest amplitude of average volatility was 3.86% (last week), 8.16% (last month), and 5.38% (last quarter).
more news about erytech pharma (eryp.pa).